Chronic Spontaneous Urticaria (CSU) Archives

Briquilimab breaks walls in chronic spontaneous urticaria

Presented By

Prof. Martin Metz, Charité Universitätsmedizin, Germany

Trial

Phase 1/2, BEACON

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 15:34

Anti-KIT antibody: the next frontier in CSU treatment?

Presented By

Prof. Martin Metz, Charité-University Hospital Berlin, Germany

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:33

What’s new in clinical dermatology?

Presented By

Dr Tamar Nijsten, Erasmus University Medical Centre, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:31

Remibrutinib reduces itch, sleep problems, and activity impairment in patients with CSU

Presented By

Dr Ana Giménez-Arnau, Autonomous University and Pompeu Fabra University, Spain

Trial

Phase 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:13

Biomarkers predicting response of different CSU treatments in children

Presented By

Mr Alex Nguyen, McGill University, Canada

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:35

Autologous serum therapy benefits chronic spontaneous urticaria

Presented By

Dr Akash Agarwal, IMS and SUM Hospital Bhubaneswar, India

Conference

ICD 2021

Type

News article

2 December 2021 17:35

CSU: Ligelizumab likely safe and effective for adolescents

Presented By

Prof. Bülent Şekerel, Hacettepe University, Turkey

Trial

Phase 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:29

D-Dimer as future biomarker in CSU management?

Presented By

Dr Antonio Cristaudo, San Gallicano Dermatological Institute, Italy

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 18:41

Novel anti-IgE drug enables durable urticaria control

Presented By

Dr Diane Baker, Baker Allergy, Asthma, and Dermatology Clinic, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 20:22